Chromosome 3, 5 and 11 genes involved in premature canities
CA 2491235 A1 · Owner: Antonarakis, Stylianos · Inventors: Deloche, Claire; De Lacharriere, Olivier; Blouin, Jean-Louis
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention concerns the use of at least one polynucleotide fragment comprising at least 18 consecutive nucleotides whereof the sequence corresponds to all or part of a human chromosome 3 gene selected among KIAA1042 CCK, CACNA1D, ARHGEF3 and AL133097 or whereof the sequence corresponds to all or part of a human chromosome 5 gene selected among KLHL3 HNRPAO, CDC25C, EGR1, C5orf6, C5orf7, LOC51308 ETF1, HSPA9B, PCDHAI to PCDHA13, CSF1R RPL7, PDGFRB, TCOF1, AL133039, CD74, RPS14 NDST1, G3BP, GLRA1, C5orf3, MFAP3, GALNTIO and FLJ11715 genes or whereof the sequence corresponds to all or part of a human chromosome 11 gene selected among GUCYIA2 CULS, ACAT1, NPAT, ATM, AF035326, AF035327 …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 9, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 9, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 9, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.